Cargando…

Epithelial Ovarian Cancer—Varied Treatment Results

Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the P...

Descripción completa

Detalles Bibliográficos
Autores principales: Millert-Kalińska, Sonja, Przybylski, Marcin, Pruski, Dominik, Stawicka-Niełacna, Małgorzata, Mądry, Radosław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379362/
https://www.ncbi.nlm.nih.gov/pubmed/37510484
http://dx.doi.org/10.3390/healthcare11142043
_version_ 1785079998087954432
author Millert-Kalińska, Sonja
Przybylski, Marcin
Pruski, Dominik
Stawicka-Niełacna, Małgorzata
Mądry, Radosław
author_facet Millert-Kalińska, Sonja
Przybylski, Marcin
Pruski, Dominik
Stawicka-Niełacna, Małgorzata
Mądry, Radosław
author_sort Millert-Kalińska, Sonja
collection PubMed
description Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the Poznań University of Medical Sciences (SKPP). The relationships among starting treatment in our centre, the type of first intervention, and the final decision were significant (p < 0.001). Patients in the SKPP group were more likely to primarily have a laparoscopy and less likely to have an exploratory laparotomy. Neoadjuvant chemotherapy (NACT) after a laparotomy was less often a final decision among SKPP patients (9% vs. 22%), in contrary to NACT after a laparoscopy (23% vs. 4%). Factors affecting the shortening of progression-free survival (PFS) were an advanced stage of the disease, a histopathological diagnosis, the type of cytoreduction, and the final decision. Significance according to the final decision was revealed for PDS vs. NACT after a laparotomy (p < 0.001) and for PDS vs. NACT after a laparoscopy (p = 0.011). Our study supports the benefits of treating ovarian cancer in an oncology centre with a high patient throughput. Further observations might also answer the question about overall survival (OS).
format Online
Article
Text
id pubmed-10379362
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103793622023-07-29 Epithelial Ovarian Cancer—Varied Treatment Results Millert-Kalińska, Sonja Przybylski, Marcin Pruski, Dominik Stawicka-Niełacna, Małgorzata Mądry, Radosław Healthcare (Basel) Article Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the Poznań University of Medical Sciences (SKPP). The relationships among starting treatment in our centre, the type of first intervention, and the final decision were significant (p < 0.001). Patients in the SKPP group were more likely to primarily have a laparoscopy and less likely to have an exploratory laparotomy. Neoadjuvant chemotherapy (NACT) after a laparotomy was less often a final decision among SKPP patients (9% vs. 22%), in contrary to NACT after a laparoscopy (23% vs. 4%). Factors affecting the shortening of progression-free survival (PFS) were an advanced stage of the disease, a histopathological diagnosis, the type of cytoreduction, and the final decision. Significance according to the final decision was revealed for PDS vs. NACT after a laparotomy (p < 0.001) and for PDS vs. NACT after a laparoscopy (p = 0.011). Our study supports the benefits of treating ovarian cancer in an oncology centre with a high patient throughput. Further observations might also answer the question about overall survival (OS). MDPI 2023-07-17 /pmc/articles/PMC10379362/ /pubmed/37510484 http://dx.doi.org/10.3390/healthcare11142043 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Millert-Kalińska, Sonja
Przybylski, Marcin
Pruski, Dominik
Stawicka-Niełacna, Małgorzata
Mądry, Radosław
Epithelial Ovarian Cancer—Varied Treatment Results
title Epithelial Ovarian Cancer—Varied Treatment Results
title_full Epithelial Ovarian Cancer—Varied Treatment Results
title_fullStr Epithelial Ovarian Cancer—Varied Treatment Results
title_full_unstemmed Epithelial Ovarian Cancer—Varied Treatment Results
title_short Epithelial Ovarian Cancer—Varied Treatment Results
title_sort epithelial ovarian cancer—varied treatment results
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379362/
https://www.ncbi.nlm.nih.gov/pubmed/37510484
http://dx.doi.org/10.3390/healthcare11142043
work_keys_str_mv AT millertkalinskasonja epithelialovariancancervariedtreatmentresults
AT przybylskimarcin epithelialovariancancervariedtreatmentresults
AT pruskidominik epithelialovariancancervariedtreatmentresults
AT stawickaniełacnamałgorzata epithelialovariancancervariedtreatmentresults
AT madryradosław epithelialovariancancervariedtreatmentresults